Scienture Holdings (SCNX) Q1 2026 earnings summary

Executive summary

• Focus shifted to specialty pharma after divesting legacy subsidiaries in 2025, with resources now dedicated to developing and commercializing branded pharmaceutical products, especially in CNS and CVS therapeutic areas.

• Commercial launch of ARBLI™ (SCN-102) in Q3 2025 marked the first FDA-approved ready-to-use oral liquid losartan in the U.S.; pipeline includes additional late-stage candidates targeting migraine, pain, and thrombosis.

• Strategic realignment included the sale of non-core assets, streamlining operations, and using proceeds to accelerate Scienture's product development and commercialization.

Financial highlights

• Q1 2026 revenue was $56,325, up from $10,258 in Q1 2025, driven by ARBLI™ sales ramp.

• Gross profit rose to $53,850 from $673 year-over-year; gross margin improved significantly.

• Net loss increased to $3,402,264 from $3,063,997, reflecting higher R&D and professional fees.

• Adjusted EBITDA loss was $2,939,166, compared to $2,475,856 in Q1 2025.

• Cash at March 31, 2026 was $3.54 million, down from $6.66 million at year-end 2025.

Outlook and guidance

• Management expects continued revenue growth from ARBLI™ and plans to advance additional pipeline products toward commercialization, with SCN-104 and SCN-106 targeted for regulatory filings in 2027–2028.

• Ongoing need for additional capital to fund operations and pipeline development; recent $11.42 million secured note financing in April 2026 to support working capital and R&D.

• Substantial doubt remains about ability to continue as a going concern without further capital raises or improved operating cash flow.